α-Therapy with ²²³Ra-Dichloride for Bone Metastasis of Castration Resistant Prostate Cancer

Abstract

It is good news for us that radium dichloride which is an α emitter radionuclide was approved in Japan as a treatment option for the metastatic castration-resistant prostate cancer. Impairment of the quality of life due to the bone metastasis is a big problem, and you should avoid especially in patients with prostate cancer because natural history and progress of prostate cancer are relatively slow even if bone metastases occurs. In addition, the appearance of the therapeutic option that extends duration of survival in addition to the reduction of skeletal related event (SRE) has a positive impact on treatment modalities for castration resistance prostate cancer. As described, there is still the problems that should be resolved for the establishment of optimal usage of radium dichloride in management of castration resistance prostate cancer with bone metastasis.